CTIP Accelerator Announces 2023 Winners for Catalyzing Pediatric Innovation Annual Grant Competition
LOS ANGELES, CALIFORNIA - AUGUST 21, 2023 - The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP), centered at Children's Hospital Los Angeles, awarded $200,000 in seed grants on August 21, 2023, to accelerate medical device projects specifically designed to improve the safety and delivery of care to infants and children.
Five innovators developing novel devices and technologies for pediatric patients were selected as winners for CTIP’s seventh annual Catalyzing Pediatric Innovation (CPI) Grant competition.
Children have long been an underserved population in the technology space, with many having to deal with ill-fitted medical devices and a lack of access to effective diagnostic or therapeutic devices. Pediatric medical device innovators face financial, regulatory, and scientific barriers to get their solutions in the hands of patients and providers. The CPI Grant is one way CTIP helps founders target these obstacles, alongside our platform of services to help guide the advancement of pediatric medical devices.
CPI Grant applicants proposed many innovative devices designed to address serious complications in children, covering all pediatric age ranges and care settings. Applications included device projects across 18 different pediatric subspecialties, all anticipated FDA device classes (Class I, II, and III), and were received from 25 states, including 36% of applications from California.
The 2023 winners are as follows:
The Close and Comfortable: 1.5T Flexible Pediatric MR Body Array is a dramatically faster, more accurate, and more comfortable Pediatric MR Body Array for 1.5T scanners to get closer to all patients.
LinkedIn: InkSpace Imaging Twitter: @InkSpaceImaging
Boppli is designed to be a wearable, non-invasive, wireless blood pressure monitor for fragile neonatal infants in the NICU; it is designed to be easier to use than a standard blood pressure cuff and safer than an arterial line (FDA clearance pending).
LinkedIn: PyrAmes Twitter: @PyramesInc
Atrial Innovations
AtriLock is the first Atrial Septal Defect Occluder designed for future left atrium access, ensuring patients have the maximum flexibility in treatment options should future procedures be necessary.
FlowSense Usability Study in Support of FDA Approval is an FDA breakthrough designated diagnostic wearable solution for hydrocephalus that can detect cerebrospinal fluid flow bedside in minutes without wires, needles, capital equipment, or radiation.
Facebook: Rhaeos, Inc. Instagram: @rhaeos LinkedIn: Rhaeos Twitter: @rhaeos
The Percutaneous Solutions for Redirecting Blood Flow in Patients with Congenital Heart Disease is a device that leverages the current Renata growth stent technology in a new application aimed to redirect blood flow in children suffering from congenital heart disease and will serve as a lifelong alternative to multiple open heart surgeries.
LinkedIn: Renata Medical
READ FULL ARTICLE HERE